AVITA Medical Announces Achievement of Co-Primary Endpoints in Updated Analysis of Pivotal Trial of RECELL® System for Soft Tissue Repair

November 9, 2022

https://www.globenewswire.com/news-release/2022/11/09/2552596/0/en/AVITA-Medical-Announces-Achievement-of-Co-Primary-Endpoints-in-Updated-Analysis-of-Pivotal-Trial-of-RECELL-System-for-Soft-Tissue-Repair.html

VALENCIA, Calif. and MELBOURNE, Australia, Nov. 09, 2022 (GLOBE NEWSWIRE) — AVITA Medical, Inc. (NASDAQ:RCEL, ASX:AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced achievement of co-primary endpoints as a result of updated analysis of data from its clinical trial evaluating the safety and effectiveness of the RECELL® System for soft tissue repair.

Read more at globenewswire.com

Related news for (RCEL)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.